KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBIT: 2009-2025

Historic EBIT for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to -$8.7 million.

  • Arbutus Biopharma's EBIT rose 59.61% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.8 million, marking a year-over-year increase of 43.70%. This contributed to the annual value of -$76.3 million for FY2024, which is 2.28% up from last year.
  • Latest data reveals that Arbutus Biopharma reported EBIT of -$8.7 million as of Q3 2025, which was down 681.92% from $1.5 million recorded in Q2 2025.
  • Arbutus Biopharma's EBIT's 5-year high stood at $1.5 million during Q2 2025, with a 5-year trough of -$25.7 million in Q1 2025.
  • Moreover, its 3-year median value for EBIT was -$19.4 million (2024), whereas its average is -$17.0 million.
  • Per our database at Business Quant, Arbutus Biopharma's EBIT plummeted by 58.68% in 2023 and then surged by 106.89% in 2025.
  • Over the past 5 years, Arbutus Biopharma's EBIT (Quarterly) stood at -$20.8 million in 2021, then declined by 8.49% to -$22.6 million in 2022, then grew by 8.04% to -$20.7 million in 2023, then surged by 32.84% to -$13.9 million in 2024, then surged by 59.61% to -$8.7 million in 2025.
  • Its EBIT was -$8.7 million in Q3 2025, compared to $1.5 million in Q2 2025 and -$25.7 million in Q1 2025.